English
norskHaptoglobin 2-2 Genotype, Patient, and Graft Survival in Renal Transplant Recipients
Permanent lenke
https://hdl.handle.net/10037/12108
Dato
2017-09-22Type
Journal articleTidsskriftartikkel
Peer reviewed
Sammendrag
Background:
Cardiovascular disease is the leading cause of death in renal transplant recipients (RTRs). An association between haptoglobin genotype 2 - 2 and cardiovascular disease has been found in patients with diabetes mellitus and liver transplant recipients. To date, the role of haptoglobin genotype after renal transplantation has not been studied.
Methods:
In this single centre re trospective cohort study of 1975 adult Norwegian RTRs, transplanted between 1999 and 2011, we estimated the risk of all - cause and cardiovascular mortality and overall and death censored graft loss for patients with haptoglobin genotype 2 - 2 compared with genotype 2 - 1 or 1 - 1 , after adjustment for confounders and competing risks.
Results:
We found no associations between haptoglobin genotype 2 - 2 and cardiovascular mortality (subdistributional hazard ratio [SHR] 1.08, 95% confidence interval [CI] 0.78 - 1.49, p=0.63). We also fail ed to detect any association between haptoglobin 2 - 2 genotype and all - cause mortality, overall graft loss and death censored graft loss. Similar results were found in the subpopulation of diabetic RTRs.
Conclusion:
In this large cohort of kidney transplant recipients, we could not demonstrate any association between haptoglobin 2 - 2 genotype and patient or graft survival after renal transplantation.
Cardiovascular disease is the leading cause of death in renal transplant recipients (RTRs). An association between haptoglobin genotype 2 - 2 and cardiovascular disease has been found in patients with diabetes mellitus and liver transplant recipients. To date, the role of haptoglobin genotype after renal transplantation has not been studied.
Methods:
In this single centre re trospective cohort study of 1975 adult Norwegian RTRs, transplanted between 1999 and 2011, we estimated the risk of all - cause and cardiovascular mortality and overall and death censored graft loss for patients with haptoglobin genotype 2 - 2 compared with genotype 2 - 1 or 1 - 1 , after adjustment for confounders and competing risks.
Results:
We found no associations between haptoglobin genotype 2 - 2 and cardiovascular mortality (subdistributional hazard ratio [SHR] 1.08, 95% confidence interval [CI] 0.78 - 1.49, p=0.63). We also fail ed to detect any association between haptoglobin 2 - 2 genotype and all - cause mortality, overall graft loss and death censored graft loss. Similar results were found in the subpopulation of diabetic RTRs.
Conclusion:
In this large cohort of kidney transplant recipients, we could not demonstrate any association between haptoglobin 2 - 2 genotype and patient or graft survival after renal transplantation.
Beskrivelse
Submitted manuscript version. Published version available at https://doi.org/10.1177/1526924817732020 .